StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
HIPOLIN.BO$89.14+0.00%
Fair $89.14+0.0%

HIPOLIN.BO

Hipolin Limited

Consumer Defensive / Household & Personal ProductsBSE

$89.14

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $89.14Fund rank 25/100 · Data gapFallback financials|
SA 27/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-32.1M · quality 42.3/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 13/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

27/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -40.2%, below the 5% threshold
Thesis & Journal · HIPOLIN.BOLocal privado en este navegador · Hipolin Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$279M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-40.2%

↓

Gross Margin

25.7%

↓

Debt/Equity

0.35

↓
52-Week Range$89
$45$119

TradingView lightweight chart

HIPOLIN.BO price, volumen y niveles de valoración

Último $90.95Periodo -45.7%
Fair value: $89.14

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+20.9%

FCF CAGR

—

FCF margin

-14.9%

FCF / Net income

0.98x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $215.6M · net income $-32.8M · FCF $-32.1M

2022-FY → 2025-FY

Gross margin

25.7%+5.9% pts

Operating margin

-15.7%-5.1% pts

Net margin

-15.2%-6.1% pts

FCF margin

-14.9%-37.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$215.6M$215.6M$197.3M$155.6M$122.2M
Net Income$-32.8M$-32.8M$-8.9M$76.3M$-11.1M
EBITDA$-29.4M$-29.4M$-7.1M$77.5M$-9.9M
EPS-10.47-10.47-2.8324.00-3.56
Gross Margin25.7%25.7%25.2%23.1%19.8%
Operating Margin-15.7%-15.7%-6.5%-8.2%-10.6%
Net Margin-15.2%-15.2%-4.5%49.0%-9.1%
Balance Sheet
Debt/Equity0.350.350.180.060.23
Cash Flow
Free Cash Flow$-32.1M$-32.1M$-17.1M$-54.2M$27.7M
Returns
ROE-40.2%-40.2%-7.8%62.0%-23.8%
Valuation
P/B3.433.43———
Growth & Yield
Revenue Growth9.3%9.3%26.8%27.3%—
EPS Growth-270.0%-270.0%-111.8%774.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -10.7%

Total return

-10.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-2.83 → -10.47

Residual

-10.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-10.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.